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T here are retrospective1,2 and prospective3,4 singlecenter studies that show decreased morbidity and
mortality with the use of preincision intra-aortic bal-
loon pumps (IABPs) in high-risk patients undergoing
coronary artery bypass grafting (CABG). However,
these studies included many patients with ongoing
myocardial infarction and preoperative cardiogenic
shock, which are generally accepted therapeutic rather
than prophylactic indications for IABPs.
The Alabama CABG Cooperative Project is a
statewide process-oriented project involving all hospi-
tals performing CABG in the state.5 As part of the pro-
ject, numerous demographic, procedural, and outcome
variables were gathered. Two of these variables were
use of an IABP (yes/no) and time of IABP insertion rel-
ative to the CABG procedure (preincision/intraopera-
tive/postoperative).
Objective: The objective of this study was to determine whether preincision
use of an intra-aortic balloon pump improves survival and shortens postop-
erative length of stay in hemodynamically stable, high-risk patients under-
going coronary artery bypass grafting.
Methods: A post hoc analysis of the Alabama CABG Cooperative Project
database was performed by using propensity scores to model the likelihood
of receiving a prophylactic preincision intra-aortic balloon pump. Every
patient receiving a prophylactic preincision balloon pump was matched with
another patient of similar propensity score who did not receive one. We then
compared outcomes for matched pairs.
Results: There were 7581 patients of whom 592 received a prophylactic
preincision balloon pump. Patients with preoperative renal insufficiency,
heart failure, or left main coronary artery disease, or who had undergone pre-
vious bypass grafting were significantly more likely to receive a prophylac-
tic preincision balloon pump. By using propensity scores, we matched 550
patients who received a prophylactic preincision balloon pump with 550 who
did not. Survival did not significantly differ by whether a prophylactic prein-
cision balloon pump was used. However, surviving patients who received a
preincision balloon pump had a significantly shorter postbypass length of
stay (7 ± 7.3 days) than did matched patients not receiving a balloon pump
(8 ± 6.2 days; P < .05).
Conclusions: No survival advantage was found for use of a prophylactic intra-
aortic balloon pump in hemodynamically stable, high-risk patients undergo-
ing bypass grafting, as opposed to placing a balloon pump on an “as need-
ed” basis during or after the operation. However, the patients receiving the
balloon pump had improved convalescence as shown by significantly short-
er length of stay.  (J Thorac Cardiovasc Surg 2000;120:1112-9)
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The present study analyzes data gathered by the
Alabama CABG Cooperative Project to determine the
effect of prophylactic preincision IABP use in hemo-
dynamically stable, but high-risk patients undergoing
CABG by comparing risk-adjusted patient outcomes.
Patients with evidence of very recent or impending
myocardial damage or with hemodynamic instability
were not included in this analysis. Only the demo-
graphic variables and descriptors of patient disease that
were available before the operation were used to define
risk. The hypothesis tested is that prophylactic preinci-
sion IABP placement in hemodynamically stable, high-
risk patients undergoing CABG favorably influences
in-hospital mortality and post-CABG length of hospital
stay (LOS).
Methods
The Alabama CABG Cooperative Project is an extension of
a statewide Cooperative Cardiovascular Project that began in
1994.5 For the initial phase of the Alabama CABG
Cooperative project, a sample of Medicare patients who
underwent CABG surgery was selected. This sample consist-
ed of all Medicare patients discharged from participating hos-
pitals between July 1, 1995, and June 30, 1996 (initial round
of data abstraction) and between January 1, 1998, and June
30, 1998 (second round of data abstraction). Patients with a
diagnosis-related group (DRG) of 106 (coronary artery
catheterization and CABG surgery during the same admis-
sion) or DRG 107 (only CABG surgery during the admission)
were included. Patients with DRG 104 (cardiac valve proce-
dure with catheterization), DRG 105 (cardiac valve procedure
without catheterization), and DRG 468 (extensive procedure
unrelated to principal diagnosis) were excluded.
Initially we had data on 9235 CABG procedures. After delet-
ing missing data on clinical outcome, sex, and race, records for
8972 hospitalizations were left for analysis. In our analysis,
placement of an IABP is considered therapeutic rather than pro-
phylactic for patients with impending or very recent myocardial
damage or for patients with hemodynamic instability. We there-
fore excluded the following patients: (1) those in shock and/or
undergoing mechanical ventilation before the operation (N =
377) and (2) those undergoing emergency CABG, those who
had undergone percutaneous transluminal coronary angioplasty
(PTCA) within the 6 hours preceding CABG, or those who had
a documented myocardial infarction no more than 3 days before
the operation (N = 1198). There were 184 patients in the groups
1 and 2 described in the previous sentence. Hence, we were left
with 7581 patients for our analyses, of whom 592 received a
preincision IABP. Patients undergoing intraoperative or postop-
erative IABP were included in the group not receiving preinci-
sion IABP.
Analyses. After performing descriptive statistics on the
CABG Project dataset, we engaged in the following steps. 
Step l. Generation of a propensity score to model the like-
lihood of prophylactic preincision IABP use, based on patient
characteristics available to the surgeon preoperatively, and
likely to influence the surgeon’s decision to place an IABP. 
Step 2. Bivariate analyses of associations between patient
characteristics, propensity scores, receipt of preincision
IABP, and study outcomes: mortality in-hospital and at 30,
60, 180, 360, and 1000 days, as well as postoperative LOS. 
Step 3. Development of multivariable models for each of
these outcomes (mortality and LOS) as dependent variable,
and with receipt of preincision IABP as the main independent
variable, and propensity score as well as other clinical factors
as covariates. 
Step 4. Matching of each patient receiving preincision
IABP with another patient of similar propensity score and
similar presentation based on other key variables. Outcomes
for these matched pairs were compared.
We therefore tested our hypothesis by using 2 approaches.
First, in above steps 2 and 3, we examined the association
between receipt of preincision IABP and outcome, before and
after adjusting for the a priori likelihood that the patient
would receive a preincision IABP, based on his/her likelihood
to receive one (propensity score), and on other clinical char-
acteristics. Second, in step 4, we directly compared a set of
patients who received a prophylactic preincision IABP with
Table I. Characteristics of patients who were hemodynamically stable, had no impending or very recent myocar-
dial damage, and underwent nonemergent CABG: the Alabama CABG Cooperative Project
All patients Preincision IABP No preincision IABP
N 7581 592 6989
Age (mean y) (SD) 71 (7) 71 (8) 71 (8)
Race (% African American) 9.1 8.4 9.2
Sex (% female)* 34.6 25.3 35.3
Postincision IABP (%)* 4.30 0 4.7
Renal insufficiency (%) 6.3 9.3 6.0
Heart failure (%)* 25.9 65.7 22.5
Diabetes (%) 29.9 31.9 29.8
Comorbidity score (SD) 1.83 (0.92) 1.85 (0.93) 1.83 (0.92)
Left main artery stenosis > 70%* 9.6 15.5 9.1
Had previous CABG surgery (%)* 13.5 36.7 11.5
*P < .01 for comparisons of those who received preincision IABP versus those who did not.
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another who did not, even though for each pair their likeli-
hood of receiving a preincision IABP was similar.
Development of the propensity score model. The propen-
sity score method, described by Rosenbaum and Rubin,6,7
allows a direct estimation of the likelihood of receipt of the
treatment under study (in our case, preincision IABP) on the
basis of the variables deemed important in making the treat-
ment decision. The propensity score can then be used to
adjust globally for the characteristics that were deemed influ-
ential in the decision to treat or not to treat and becomes a
powerful tool for adjusting for treatment selection bias (con-
founding by indication) in observational studies such as ours.
In this study, the propensity score is the probability of IABP
insertion predicted by a multiple logistic regression (MLR)
model where actual preincision IABP receipt is the depen-
dent variable and the variables mentioned next are the inde-
pendent variables.
Currently, cardiac surgeons place or do not place a preinci-
sion IABP according to their subjective assessment of its
potential benefits. We queried 2 cardiac surgeons who
reached consensus on which of the variables collected by the
Alabama CABG Cooperative Project were influential in the
decision to insert a preincision IABP. Those variables chosen
include patient age, sex, comorbidity (index adapted from
Charlson), history of diabetes mellitus, history of prior
CABG, renal insufficiency at presentation (creatinine greater
than 2.0 mg/dL or blood urea nitrogen of 35 mg/dL or
greater, or on dialysis), congestive heart failure at presenta-
tion (ejection fraction of 0.30 or less by imaging procedure,
clinical presentation consistent with heart failure, or history
of cardiac decompensation within 2 weeks before the opera-
tion), or left main coronary artery stenosis of 70% or greater.
These were the variables used to develop our propensity
score. Other patient characteristics were deemed indications
for a preincision IABP, but as treatment rather than prophy-
laxis. Hence, these variables were used as exclusion criteria
and not in the propensity score or elsewhere in our analyses.
These variables included the following: hemodynamic insta-
bility (shock as determined by blood pressure after arrival at
hospital and before incision), initiation of mechanical venti-
lation before entering the operating room, PTCA performed
at most 6 hours before CABG, and very recent myocardial
infarction (at most 3 days before CABG).
We developed our propensity score model in several itera-
tive steps in which we categorized our variables in a way to
optimize the fit of the model to the data. Because we were
focusing on optimal prediction, we left every initial variable
in the final model, regardless of the level of statistical signif-
icance of its coefficient. We tested whether the propensity
score would adjust completely for all the covariates it incor-
porates by checking for differences in individual covariates
for patients with and without an IABP after stratifying for
quintiles of propensity score. Because several variables
showed statistically significant differences in some of the
quintiles of propensity scores, we also used them as covari-
ates in the subsequent MLR modeling outcomes. In addition,
we made similarity of those variables a matching condition
when we created matched pairs of patients receiving and not
receiving a prophylactic preincision IABP.
Case-matching procedure. Each patient who received a
preincision IABP was matched with another patient who did
not receive a preincision IABP but with a similar propensity
score (the difference in propensity score for members of the
same pair had to be < 0.03). We also matched the pairs on
those covariates where the analysis by quintile of propensity
score had suggested that there were differences between
those who did versus those who did not receive a preincision
IABP. Thus, we ensured that the members of each matched
pair were similar in terms of those characteristics deemed
influential in the decision regarding a prophylactic preinci-
sion IABP.
Table II.  Propensity score model: Adjusted odds
ratios and 95% confidence intervals (CI) for receiving
a prophylactic preincision IABP: the Alabama CABG
Cooperative Project
Adjusted 
Covariate odds ratio 95% CI
Age, y (≥ 75 vs < 75) 1.20 0.98-1.45
Sex (male vs female)* 1.31 1.07-1.61
Renal insufficiency 1.06 0.76-1.46
Heart failure† 6.63 5.50-8.00
Diabetes 1.02 0.84-1.24
Cormorbidity score (per unit increase)* 0.88 0.80-0.98
Left main artery stenosis > 70%† 1.47 1.13-1.90
Had previous CABG surgery† 4.24 3.48-5.17
C-statistic for model: 0.791.
*P < .05.
†P < .005.
Table III. Characteristics of 550 matched pairs of
patients managed with and without preincision IABP:
the Alabama CABG Cooperative Project
IABP No IABP
Variable (n = 550) (n = 550)
Propensity for IABP 0.172 0.172
IABP at any time (%)* 550 (100%) 52 (9.5%)
Model estimate, probability of 0.896 0.892
1-year survival (using propensity score)
Mean age (y) (SD) 71 (7.9) 70 (8.2)
Mean index of comorbidity (SD) 1.84 (0.81) 1.84 (0.81)
Mean postoperative LOS (d) (SD)* 7 (7.3) 8 (6.2)
African American ethnicity (N) (%) 50 (9.1) 60 (10.9)
Female sex (N) (%) 139 (25.3) 139 (25.3)
Renal insufficiency (N) (%) 43 (7.8) 43 (7.8)
Heart failure (N) (%) 354 (64.4) 354 (64.4)
Diabetes (N) (%) 177 (32.2) 177 (32.2)
Left main artery stenosis > 70% (N) (%) 68 (12.4) 68 (12.4)
Had previous CABG surgery (N) (%) 187 (34) 187 (34)
IABP at any time, IABP used at any time relative to surgery (NB: All “IABP”
patients had prophylactic preincision IABP. Some “No IABP” patients had an
intraoperative or postoperative IABP.); postoperative LOS, post-CABG hospi-
tal LOS.
*P < .05.
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Mortality modeling. For each patient, we had vital status
as of June 22, 1999, ascertained from Medicare denominator
files. Therefore, we were able to determine in-hospital mor-
tality for all patients, as well as 30-, 60-, 180-, 360- and 1000-
day mortality for most. In fact, we had length of survival,
with censoring at 374 days for all. Therefore, we were able to
perform MLR modeling to predict mortality by using for
dichotomous outcomes death in-hospital, or death at 30, 60,
180, 360, and 1000 days. We did this by using the propensity
score and other clinical characteristics as predictor variables.
We performed Cox proportional hazards analyses with
death as the outcome variable and censoring as of June 22,
1999 (hence variable follow-up time for each patient). For
all these models, actual receipt of preincision IABP was the
main independent variable, whereas propensity score and
other clinical variables were covariates. These covariates
included the variables for which quintile of propensity score
analysis had shown that the propensity score might not fully
adjust, as well as variables to adjust for hospital character-
istics, such as bed size (dichotomized at 400 beds). We
developed a statistical model that predicted a patient’s
expected risk for operative mortality according to preopera-
tive clinical factors. Potential clinical risk factors were cho-
sen on the basis of a number of previously published CABG
risk models.8-10 The details of this risk adjustment model
have been published.5 For this study, we also built models
with the study outcomes as dependent variables, receipt of
preincision IABP as main independent variable, and the pre-
viously derived risk-adjusted mortality as a covariate. The
coefficients for preincision IABP were similar to those
obtained when we used propensity scores, so we do not pre-
sent these other models.
Results
Of all 8972 CABG patients without missing data,
15.3% received an IABP either before or after incision.
Of the 7581 study patients who were potential candi-
Table IV.  Survival of 550 matched pairs, by whether prophylactic preincision IABP was inserted: the Alabama
CABG Cooperative Project
IABP No IABP
Survival time No. % No. %
In-hospital 520 94.5 522 94.9
30 days 515 93.6 519 94.4
60 days 510 92.7 511 92.9
180 days 498 90.5 498 90.5
365 days 487 88.5 484 88.0
1000 days 459 83.5 439 79.8
Fig 1. Adjusted survival of patients receiving prophylactic preincision IABP compared with all patients who did
not receive one.
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dates for a prophylactic preincision IABP, 7.8%
received one. Men, patients with preoperative renal
insufficiency, heart failure, or significant left main
stenosis, or those who had previous CABG surgery
were significantly more likely to receive prophylactic
preincision IABP (Table I).
When we developed our propensity score model,
heart failure, comorbidity score, left main stenosis, and
previous CABG remained independent predictors of
receiving a preincision IABP (Table II). The propensi-
ty score model had high discrimination, as measured by
a C-statistic of 0.79. The predicted probability of
receiving a preincision IABP, using this model, was on
average 18.5% for those 592 patients who received one
and 6.9% for those 6898 who did not. The mean pre-
dicted 1-year survival computed by using propensity
scores and other initial presentation variables but no
actual receipt of IABP was 89% for those who received
a preincision IABP and 92% for those who did not (P
< .005).
We were able to successfully match 550 pairs of
patients. For each pair, one member received a prophy-
lactic preincision IABP and the other did not, but their
propensity scores were within 3% of one another
(Table III). Mean predicted 1-year survival (computed
by using propensity scores and other clinical initial pre-
sentation variables but no actual receipt of IABP) was
not statistically significantly different depending on
whether pair members had received an IABP, confirm-
ing that we had patients with similar risk of death in the
2 groups. Unadjusted in-hospital, 30-, 60-, 180-day and
1-year survival for the matched pair members did not
differ, at a statistically significant level, by whether a
preincision IABP was received (Table IV). However,
an intermediate-term survival benefit from IABP was
suggested (Fig 1).
Of note, patients who received a preincision IABP
had a significantly shorter post-CABG LOS. This may
reflect fewer adverse events during the operation for
patients with a prophylactic preincision IABP and a
more rapid convalescence. For the matched pairs, and
excluding in-hospital deaths, those with prophylactic
preincision IABP had a mean post-CABG LOS of 7
days, compared with 8 for those without preincision
IABP (P < .05). An alternative hypothesis is that sur-
vivor bias resulted in a shorter LOS for the IABP
group. However, when the analysis was repeated to
include the patients who died, the LOS difference
remained significant and in favor of preincision IABPs
(9 ± 7.8 days versus 11 ± 7.3 days; P < .005).
When we compared unadjusted survivals in the entire
population, as opposed to just the matched pairs,
patients who had received preincision IABPs had con-
sistently lower survivals than those who had not. When
we refined these comparisons by multivariable adjust-
ment via Cox proportional hazards modeling on the
entire population, whether preincision IABP had been
received was no longer significantly associated with
survival (Table V). In fact, the hazard ratio for IABP
was less than 1 (0.90), which would suggest some ben-
eficial effect for IABP, except that the 0.90 hazard ratio
had a 95% confidence interval of 0.72 to 1.13, which
overlaps 1. Hence, no inference of a beneficial effect
should be made.
Discussion
Patients who received a preincision IABP and are
included in this study did not have evidence of very
Table V.  Proportional hazards model for 7581 patients: adjusted hazard ratios and 95% confidence intervals (CI)
for death over entire follow-up period*
Variable Adjusted hazard of death ratio 95% CI
Clinical
Received prophylactic preincision IABP 0.90 0.72-1.13
Heart failure 2.01† 1.55-2.61
Previous CABG 1.63† 1.22-2.19
Renal insufficiency 2.47† 2.09-2.93
Diabetes 1.15‡ 1.01-1.31
Comorbidity (1 unit) 1.40† 1.32-1.49
Demographic
Age older than 75 y 1.67† 1.47-1.89
Hospital
Bed size > 400 0.81† 0.71-0.91
*Model also adjusted for propensity score, race, sex, and hospital teaching status, but these coefficients were not statistically significant.
†P < .01.
‡P < .05.
recent or impending myocardial damage or of hemody-
namic instability. Nevertheless, they were identified
before CABG as candidates for a prophylactic IABP,
reflecting the surgeons’ assessment that these patients
had a high risk for cardiac death or a postoperative
morbid event.
To measure the benefit of prophylactic preincision
IABPs, we developed propensity scores for individual
patients. By using this propensity score and also adjust-
ing for additional risk factors for post-CABG death,
our study failed to convincingly demonstrate a lower
adjusted mortality for patients who received a prophy-
lactic preincision IABP, as compared with risk-
matched patients who did not receive a preincision
IABP. Thus, there did not appear to be any survival
advantage in placing an IABP before the operation in
these high-risk patients, as opposed to placing an IABP
on an “as needed” basis during or after the operation.
We did, however, find that prophylactic IABP use was
associated with a significantly shorter postoperative
LOS, indicating that these patients had an improved
convalescence. Furthermore, the trend in survival that
is evident at 1 to 3 years after the operation (Fig 1) may
become a significant survival benefit for prophylactic
IABPs as the duration of follow-up increases.
The avoidance of morbid events by prophylactic use
of an IABP, rather than by placing an IABP after acute
myocardial ischemia has already occurred, represents
an important change in the care of patients undergoing
CABG. It is, however, one that should not be taken
lightly, because the prediction of morbid events or
death in individual patients is still somewhat imprecise.
In other words, the benefit of prophylactic IABP use in
hemodynamically stable patients is achieved at the cost
of placing IABPs in some patients who would have tol-
erated CABG without IABP support.
Our findings in this study agree with Christenson’s
observation that a preincision IABP improves the high-
risk patient’s postoperative course,3,4 even though we
could not show a survival benefit. Our survival data are
also different from the retrospective single center expe-
riences of Dietl and colleagues1 and Gutfinger and
coworkers.2 The apparent inconsistencies highlight the
difficulty in addressing this complex issue and warrant
a closer look at the other studies1-4 that demonstrated
lower mortality with preincision IABP use.
The prospective randomized trials published by
Christenson and colleagues3,4 are the most compelling
evidence in support of preincision IABP use for high-
risk patients. However, 50% to 60% of the patients in
each of Christenson’s studies had unstable angina or
ongoing infarction, which is an important difference
from our study that excluded these patients from the
prophylactic IABP group. It is likely that preincision
IABP use favorably affects short-term post-CABG
mortality when it is placed before the operation as
treatment for severe unstable angina or ongoing infarc-
tion. This statement is based on published experience
with IABP support,2,11 the ability of a prophylactic
IABP to ameliorate acute intraoperative ischemia (a
cause of perioperative myocardial infarction12), and the
difficulty in promptly diagnosing new or worsening
myocardial ischemia during CABG procedures.13-15
The retrospective analysis of Dietl and colleagues1
examined 30-day mortality for patients with a left ven-
tricular ejection fraction of 0.25 or less who had CABG
with or without preoperative insertion of an IABP.
Despite a significantly higher prevalence of previous
CABG, New York Heart Association class III or IV
symptoms, emergency surgery, recent myocardial
infarction, and left main stenosis in patients who have
had IABP support, there was a significantly lower mor-
tality as compared with non-IABP patients. Of note, the
patients in Dietl’s series who received a preincision
IABP had a significantly higher prevalence of urgent or
emergency operation, intravenous nitroglycerin use,
recent (0-7 days) myocardial infarction, and unstable
angina. The issue of patients who are hemodynamically
stable and who do not have the more severe types of
unstable angina or myocardial infarction was not
addressed. It is this group of patients who pose the great-
est challenge for decisions regarding prophylactic use of
an IABP and who were the subjects in our analysis.
The article from Gutfinger and associates2 is another
retrospective study of preoperative IABP use in high-
risk patients undergoing CABG. High risk in this study
was defined by age of 70 years or older, urgent opera-
tion for failed PTCA, emergency CABG reoperation,
left main stenosis of 70% or more, left ventricular ejec-
tion fraction of 0.40 or less, and angina refractory to
medical management. The patients who received an
IABP were compared with patients who were 70 years
or older but did not receive a preoperative IABP. The
preoperative IABP patients had a significantly higher
prevalence of acute myocardial infarction and conges-
tive heart failure before the operation. This group also
had significantly lower left ventricular ejection frac-
tions and higher Parsonnet scores. The absence of a sta-
tistically significant difference in mortality between
groups was considered to be evidence for a benefit. The
outcomes of hemodynamically stable but high-risk
patients were not defined.
Synthesis of the information on preincision IABP
use1-4 indicates that this practice favorably influences
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mortality and morbidity in CABG patients with
myocardial ischemia or hemodynamic instability
before the operation. A benefit for prophylactic prein-
cision IABPs in high-risk patients requiring CABG
who have no signs of hemodynamic instability was
demonstrated by our study, but the benefit is less than
in patients with preoperative hemodynamic instability.
As more precise methods for predicting postoperative
morbidity and mortality in CABG patients become
available, the benefits of prophylactic preincision
IABP use in appropriately selected patients are likely
to increase.
A recent analysis of the Massachusetts Health Data
Consortium database16 showed wide variations among
participating hospitals in risk-adjusted rates for IABP
use at any time before, during, or after the CABG oper-
ation. This finding indicates that there is not currently
a consensus among practicing surgeons regarding the
indications for IABPs. Consensus regarding best prac-
tices in cardiac surgery has typically been achieved
slowly. However, changes in the CABG operation dur-
ing the past two decades, including an increase in the
prevalence of internal thoracic grafting and uniformity
in the dosing schedule for aspirin in CABG patients,
show that surgeons reach consensus when there are
data proving the benefit of a recommended practice.
Large multihospital studies, like the Alabama CABG
Cooperative Project5 and others,17,18 provide a mecha-
nism to evaluate the processes of care involved in car-
diac surgery. Information from cooperative regional
studies similar to the Alabama Project, accompanied by
additional prospective and retrospective research to
address specific questions, will allow surgeons to
achieve consensus on optimal processes of care and
move from consensus to implementation more rapidly
than has previously been possible.
Disclaimer
The data on which this publication is based were abstract-
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Administration, Department of Health and Human Services.
The content of this publication does not necessarily reflect
the views or policies of the Department of Health and Human
Services, nor does mention of trade names, commercial prod-
ucts, or organizations imply endorsement by the US
Government. The authors assume full responsibility for the
accuracy and completeness of the ideas presented. This arti-
cle is a direct result of the Health Care Quality Improvement
Program initiated by the Health Care Financing
Administration, which has encouraged identification of qual-
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